Opamtistomig
Asset
Bispecific antibody that blocks PD-L1 and activates 4-1BB to enhance antitumor immune responses.
- Stage
- Stage not known
- Modality
- Antibody
- Target
- CD274
- 0
- Indications
- 0
- Trials
- 1
- Developer
Indications
0In the full profile
- Target and mechanism2
- Owner and partners1
- Evidence for its targets2
- Competitors8
Every asset’s record: target, stage, trials and the evidence behind it.